A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
This is an early-phase clinical trial, often called a Phase 1 study, for a new drug named HMPL-523. It's designed for people who have lymphoma where previous treatments haven't worked or the cancer has returned. The main purpose of this study is to carefully check the safety of HMPL-523 at different doses and see if people can tolerate it well. Researchers will also learn how the body processes the medication. In addition to these safety checks, they will be looking for any early signs that the new medicine might be effective against lymphoma. This type of study is crucial for understanding new treatments before they can be tested in larger groups of people.
At a glance
What is this study about?
This study is an early-stage clinical trial for a new potential medicine called HMPL-523, designed to help people living with lymphoma. Lymphoma is a type of cancer that starts in infection-fighting cells of the immune system, called lymphocytes. Sometimes, after initial treatments, lymphoma can come back, or it might not respond to treatments as hoped. This study is specifically for individuals in that situation.
Because HMPL-523 is a new medicine, researchers first need to understand a lot about it. The main goals of this Phase 1 study are to find out if the medicine is safe to use and how well people can tolerate it. They will also be learning how the body absorbs, uses, and gets rid of the medicine. This information helps doctors understand how best to give the drug and what doses might be helpful.
While the primary focus is on safety and how the body handles the drug, researchers will also be closely watching to see if HMPL-523 shows any early signs of benefit against the lymphoma. It’s important to remember that in a Phase 1 study, finding signs of effectiveness is a secondary goal; the main aim is to ensure the drug is safe enough to study further in larger groups.
Key takeaways
- This is an early-stage study for a new lymphoma medicine, HMPL-523.
- It's for adults with lymphoma that has come back or not responded to other treatments.
- The main goals are to check the medicine's safety and how the body handles it.
- Researchers will also look for early signs that the medicine might be effective.
- Participation involves regular clinic visits for monitoring and tests.
- You can stop participating at any time.
Who may be eligible?
To be considered for this study, you must be an adult aged 18 or older. There is no upper age limit, meaning older adults may also be eligible if they meet other health requirements. Both men and women are welcome to participate.
The study is specifically looking for people who have been diagnosed with lymphoma. Crucially, your lymphoma must be considered "relapsed" (meaning it has returned after previous treatment) or "refractory" (meaning it did not get better, or actually got worse, with previous treatment).
Beyond these general points, there will be more detailed medical criteria that the study doctors will need to check. These will include things like your general health, how well your organs are working, and whether you've had certain other treatments recently. A study doctor will review all your medical information to see if this study is right for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of lymphoma?
- Has your lymphoma come back after treatment, or not responded to previous treatments?
- Are you able to attend regular clinic appointments for check-ups and tests?
- Are you comfortable potentially taking a new, experimental medicine?
What does participation involve?
If you decide to take part in this study, you would receive the new medicine, HMPL-523. Because this is an early-stage trial, you would likely have regular visits to the clinic. These visits are important for the study team to carefully monitor your health and how you are responding to the treatment. They would involve various assessments like blood tests, physical examinations, and possibly scans.
The specific details of what your participation involves – such as how often you visit, what tests you have, and the total duration of your involvement – would be explained fully by the study team. Usually, in early trials like this, the follow-up is quite intensive to ensure safety. You will also be given clear instructions on how to take the medication and what to watch out for.
Potential risks and benefits
Locations (1)
- —UnverifiedPoland
Common questions
What is lymphoma?
Lymphoma is a type of cancer that starts in white blood cells called lymphocytes, which are part of your body's immune system.
What does 'relapsed or refractory' mean?
Relapsed means your lymphoma has come back after treatment. Refractory means it didn't get better with previous treatment or got worse.
What is a Phase 1 study?
A Phase 1 study is the first stage of testing a new drug in people. It mainly focuses on checking if the drug is safe and finding the right dose.
Will I definitely get the new medicine?
Yes, in this type of early-stage study, all participants usually receive the new medicine being tested.
Will I have to pay to be in the study?
No, clinical trials usually cover the cost of the study medication and any tests or visits directly related to the research.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.